Kabi Commands Respect As It Launches First Tocilizumab Biosimilar In Europe

Subcutaneous, Intravenous Forms ‘Will Transform Treatment Landscape’

01 Nov 2023

Fresenius Kabi has kicked off November by launching its tocilizumab biosimilar Tyenne – the first biosimilar to Actemra to reach the EU.

European flags (Markus Pfaff/Shutterstock.com) — Shutterstock

Fresenius Kabi welcomed a “great testimonial of our Vision 2026 growth strategy” and a showcase of its “ambition to be leading in the biopharma segment” as it announced the European launch for the company’s Tyenne (tocilizumab) biosimilar to RoActemra – the first biosimilar tocilizumab product to reach the EU.

Endorsed by the European Medicines Agency’s Committee for Medicinal Products for Human Use in July, Tyenne in both subcutaneous (pre-filled syringe and autoinjector) and intravenous administrations was

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

‘We Can’t Keep Going On Like This’ – Biosimilars Forum’s Reed Calls For Urgent Changes In US

16 May 2025

• By Dave Wallace

As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

16 May 2025

• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

15 May 2025